4th Annual Cell Engager Summit | May 24-26 | Boston, MA
Learn from the pioneers of immunotherapy
Rosie Andre
cell engager, immune-oncology therapeutics, immuno-oncology, IO therapeutics, T-cell
0 Comment
Learn from the pioneers of immunotherapy
Ellie Saunders
cancer, CAR T, cell therapy, Oncology, T-cell
0 Comment
Engineering Smarter Adoptive Cell Therapies
Events/ Events/ Partner Content
jenna.warren@hansonwade.com
immunogenic, infectious disease, SARS-CoV-2, T-cell, vaccine
0 Comment
Cell-Mediated Therapies for Infectious Disease Summit
jenna.warren@hansonwade.com
solid tumors, T-cell, target selection, TCR, tumor microenvironment
0 Comment
Development of next-generation TCR-T products
Patients/ Views & Analysis/ Views and analysis
George Underwood
breast cancer, cancer, CAR T, patient insights, T-cell
0 Comment
Richard Staines
Adaptimmune, cancer, immuno-oncology, Juno, Kite, T-cell
0 Comment
T-cell trial will include controversial chemo agent fludarabine.
Richard Staines
Adaptimmune, cancer, synovial sarcoma, T-cell
0 Comment
Biotech says “robust” clinical response in early stage trial.
Articles/ Cancer/ Pharma Market Access/ Views and analysis
Linda Banks
4-1BB, cancer, immuno-oncology, immunotherapy, Keytruda, Oncology, Opdivo, PD-1, R&D, T-cell
0 Comment
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Richard Staines
Adaptimmune, cancer, GlaxoSmithKline, T-cell
0 Comment
Regulator asks for information on trial design.